earnings
confidence high
sentiment positive
materiality 0.65
IDEAYA Q3 cash $511M, darovasertib shows 42% ORR in 1L HLA-A2(-) MUM; registrational trial ongoing
IDEAYA Biosciences, Inc.
2023-Q3 EPS reported
-$1.44
revenue$19,463,000
- Cash, cash equivalents and marketable securities of $511.1M as of Sep 30, 2023; plus $134.7M net proceeds from follow-on and $10M GSK milestone receivable.
- Darovasertib + crizotinib in 1L HLA-A2(-) MUM: ORR 42%, median PFS 7.1 months; Phase 2/3 registrational trial ongoing with >50 sites planned.
- Darovasertib neoadjuvant in primary UM: 50% eye preservation rate (3/6 evaluable), tumor shrinkage in 83% of evaluable patients.
- IDE161 received FDA Fast Track for BRCA1/2 ovarian and breast cancer; Phase 1 expansion initiated in HRD+ tumors.
- IND clearance for GSK101 (Pol Theta) triggered $7M milestone; Werner Helicase DC selected with $3M milestone; IND targeted in 2024.